Notably, 75% of KMT2Ar patients in our cohort had TP53 alterations at relapse, which have recently been associated with adverse prognosis in KMT2Ar B-ALL [45]. This evidence concerns the gene TP53 and precursor B-cell acute lymphoblastic leukemia.